Geninus

Geninus AAQS

The The AAQS of Geninus (389030.KQ) as of Nov 4, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Geninus has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Geninus in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Geninus AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 KRW
Jan 1, 2019
2.00 KRW
Jan 1, 2020
2.00 KRW
Jan 1, 2021
2.00 KRW
Jan 1, 2022
2.00 KRW
Jan 1, 2023
2.00 KRW
Jan 1, 2024
2.00 KRW
Jan 1, 2025
2.00 KRW
The Geninus AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geninus stock

The AAQS of Geninus is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Geninus since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Geninus

All Key Metrics — Geninus